Central Pharmaceutical Joint Stock Company No3 (HNX:DP3)

HNX:DP3 Revenue

Central Pharmaceutical Joint Stock Company No3 had revenue of 128.76B VND in the quarter ending June 30, 2026, with 36.63% growth. This brings the company's revenue in the last twelve months to 515.53B, up 29.68% year-over-year. In the year 2025, Central Pharmaceutical Joint Stock Company No3 had annual revenue of 437.93B with 4.90% growth.

• Revenue (ttm): 515.53B
• Revenue Growth: +29.68%
• P/S Ratio: 2.55
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 1.32T

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	437.93B	20.44B	4.90%
Jan 1, 2025	417.49B	7.75B	1.89%
Jan 1, 2024	409.73B	-75.34B	-15.53%
Dec 31, 2022	485.07B	104.00B	27.29%
Dec 31, 2021	381.08B	-14.64B	-3.70%

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 24, 2026

Data Sources Report a data error